Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.32 |
| ▸ | WRN | Q14191 | 4/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.30 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405232 | 0.87 | — | — | |
| SCHEMBL6398254 | 0.82 | APP (0.32) | APPESR1ESR2HSD17B2HSD17B1 | |
| SCHEMBL6408010 | 0.82 | — | — | |
| SCHEMBL6396490 | 0.74 | ESR1 (0.30) | APPESR1ESR2ESRRG | |
| SCHEMBL6402237 | 0.73 | LMNA (0.33) | WRN | |
| SCHEMBL6402240 | 0.71 | LMNA (0.34) | APPESR1ESR2HSD17B2ESRRG | |
| SCHEMBL6318053 | 0.71 | NFKB1 (0.38) | — | |
| SCHEMBL6399807 | 0.67 | ESR1 (0.30) | APPESR1ESR2ESRRG | |
| SCHEMBL6403483 | 0.67 | HSD17B2 (0.33) | APPHSD17B2HSD17B1 | |
| SCHEMBL6319387 | 0.63 | MEN1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | claimed |
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | disclosed |
| US-20050059658-A1 | Pyridazinone | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | APOB, LDLR, LPL | APP 374/4885WRN 3480/4885ESR1 398/4885 |
| US-20050059658-A1 | Pyridazinone | TYMP, TPMT, PDXK | APP 3857/4885WRN 1057/4885ESR1 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.